Sign In
Buy CRSP
$48.15
+1.16 (+2.47%)
At Close: Jul 21, 2026
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
10:00am, Monday, 02'nd Oct 2023
Editas Medicine and CRISPR Therapeutics are racing towards the same market. It looks like Bluebird Bio is going to be the player to beat in that market.
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
10:07pm, Sunday, 01'st Oct 2023
These three companies have a proven ability to develop innovative products in the healthcare field. All three have performed poorly on the market over the past year, but their prospects remain intact.
3 Cathie Wood Stocks Set to Explode Higher
07:45pm, Sunday, 01'st Oct 2023
Love her or loathe her, Cathie Wood's magnetic pull on the investment world remains undiminished. Wood has uniquely curated portfolios brimming with disruptive tech firms and ambitious start-ups offer
Futurescape: Betting Big on These 3 Next-Gen Tech Stocks
05:00pm, Sunday, 01'st Oct 2023
In an era of rapid technological advancement and groundbreaking innovations, the stock market is constantly abuzz with opportunities and potential pitfalls. Amidst this ever-evolving landscape, three
3 No-Brainer Growth Stocks to Buy in October
08:30am, Sunday, 01'st Oct 2023
October has typically been a solid month for stocks. CRISPR Therapeutics, DraftKings, and Roivant Sciences are three growth stocks that screen as top buys right now.
Don't Miss the Boom: 3 Pharma Stocks Set to Explode Higher
02:56pm, Wednesday, 27'th Sep 2023
The pharmaceuticals market has taken a bit of a breather in recent weeks after an exhilarating rally earlier this year. But seasoned investors know the ups and downs are part of the natural ebb and fl
From Dust to Diamonds: 7 Undervalued Stocks With Sparkling Prospects
02:48pm, Wednesday, 27'th Sep 2023
In the vast equities landscape, hidden gems are waiting to be unearthed. Like diamonds in the rough, these undervalued stocks possess the potential to shine brightly in an investment portfolio.
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
09:01am, Wednesday, 27'th Sep 2023
ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise
Are Gene Therapy Stocks The Market's Next Big Winners?
08:06am, Monday, 25'th Sep 2023
It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD
2 Cathie Wood Stocks to Buy Hand Over Fist Right Now
09:10am, Sunday, 24'th Sep 2023
Cathie Wood is a visionary investor with an eye toward disruptive new technology. Tesla and Crispr Therapeutics are two of her top holdings that screen as stellar buys right now.
CRISPR Therapeutics: CEO Targets $25bn Valuation - Exa-Cel Approval Is First Step
05:14pm, Wednesday, 20'th Sep 2023
CRISPR Therapeutics has a partnership with Vertex over Exa-Cel, a potentially curative therapy for Sickle Cell Disease and beta thalassemia. The FDA will hold an Advisory Committee meeting before the
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
07:21am, Wednesday, 20'th Sep 2023
CRISPR Therapeutics and Bluebird Bio each have potential growth catalysts coming in the next 12 months. CRISPR Therapeutics has a powerful ally and plenty of cash.
Flee to Healthcare Stocks if Recession Rears its Head?
07:04am, Wednesday, 20'th Sep 2023
If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.
Where Will CRISPR Therapeutics Be in 5 Years?
09:53am, Tuesday, 19'th Sep 2023
CRISPR's financials look decent considering its position, and they should improve. The biotech may be close to receiving approval of its treatment for sickle cell disease.
Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics
10:07am, Friday, 15'th Sep 2023
The timing of upcoming catalysts is a key consideration when comparing biotechs. Recursion Pharmaceuticals may make more revenue soon, but not from its pipeline.
